comparemela.com

Latest Breaking News On - Dr reddys laboratories limited stock exchange - Page 1 : comparemela.com

Sub: Intimation - Form 6-K | MarketScreener

Sub: Intimation The United States Food & Drug Administration today completed a GMP inspection at our API manufacturing facility in Bollaram, Hyderabad . The inspection was. | June 20, 2023

Dr Reddy s Successfully Completes Phase I Study (IV Route) of DRL_TC, a Proposed Biosimilar of Tocilizumab

Tocilizumab is an important anti-rheumatic agent used in the treatment of adult patients with moderate to severe active rheumatoid arthritis who have had an inadequate response to one or more. | June 5, 2023

Dr Reddy Laboratories : Intimation under Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 - Schedule of Analyst / Institutional Investor Meetings - Form 6-K

Sub: Transcript of the Earnings call conducted on May 10, 2023 - Form 6-K

Sub: Transcript of the Earnings call conducted on May 10, 2023 Pursuant to Regulation 30 of Securities and Exchange Board of India Regulations, 2015, please find enclosed the. | May 16, 2023

Dr Reddy s Laboratories on Pace for Largest Percent Decrease Since July 2021 -- Data Talk

Dr. Reddy s Laboratories Ltd. Sponsored ADR is currently at $55.04, down $3.51 or 5.99% Would be lowest close since March 24, 2023, when it closed at $54.78 On pace for largest. | May 11, 2023

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.